English Українська
  • Main
  • Useful links
  • Information for Contributors
  • About
  • Editorial board

  • Article
    Ya. O. Yemchenko, I. P. Kaydashev, K. Ye. Ishcheykin, O. V. Bezeha, K. V. Vasylyeva, Ya. O. Oliinichenko, L. A. Bolotna


    About the author: Ya. O. Yemchenko, I. P. Kaydashev, K. Ye. Ishcheykin, O. V. Bezeha, K. V. Vasylyeva, Ya. O. Oliinichenko, L. A. Bolotna
    Type of article Scentific article
    Annotation Psoriasis is the most common chronic, genetically determined autoimmune polyetiologic inflammatory disease with impaired epidermal proliferation, provoked by exogenous and endogenous factors and manifested by erythematous scaly elements, papules and plaques. Despite the widespread prevalence of psoriasis and a large number of studies on this problem, there is still no single view of the pathogenesis of this dermatosis. For an objective understanding of the pathogenesis of psoriasis, it is necessary to consider the insufficiently studied comorbidity of this pathology. Recently, an undeniable link between psoriasis and obesity has been proven. Taking into account the current data on the role of systemic inflammation underlying the development of both psoriasis and obesity, the study of molecular mechanisms of its development, and taking into account the role of proinflammatory nuclear transcription factors, thiazolidinediones are the pathogenetically determined drug of choice for the treatment of these diseases. In this study, we determined the efficacy of using 45 mg of pioglitazone once daily for six months in the complex treatment of patients with moderate vulgar psoriasis with concomitant alimentary obesity of I-II degree by clinical and immunological studies of systemic inflammation. Analyzing the study results, it was found that long-term use of 45 mg of pioglitazone was effective, led to a decrease in systemic inflammation, and contributed to a milder course of psoriasis in case of recurrent relapse of the disease.
    Tags psoriasis,alimentary obesity,systemic inflammation,treatment
    • Babak OYa, Yarmish NV, Shkolnik VV. Ozhirіnnya yak puskoviy mehanіzm adipotsitokіnovoho kaskadu. Medytsyna transportu Ukrayiny. 2022; 2: 94–99. [in Ukrainian].
    • Yemchenko YO, Ischeykin KE, Kaidashev IP. Aspekty formuvannia personifikovanoho pidkhodu do likuvannia komorbidnosti psoriatychnoyi khvoroby. 2019; 2 (151):34–38. doi: 10.29254/2077-4214-2019-2-2-151-34-38. [in Ukrainian]
    • Yemchenko Ya, Ishcheikin K. Deiaki spilni aspekty patohenezu psoriazu ta metabolichnoho syndromu. World of medicine and biology. 2013;1(36):176–180. [in Ukrainian]
    • Atkinson RL. Could viruses contribute to the worldwide epidemic of obesity Int J Pediat Obes. 2018; 3: Suppl 1: 37–43. doi: 10.1080/17477160801896754.
    • Bertheloot D, Latz E. HMGB1, IL-1a, IL-33 and S100 proteins: dualfunction alarmins. Cell Mol Immunol. 2017; 14(1):43–64. doi: 10.1038/cmi.2016.34.
    • Bissonnette R, Fuentes-Duculan J, Mashiko S, Li X, Bonifacio KM, Cueto I, Suárez-Fariñas M, Maari C, Bolduc C, Nigen S, Sarfati M, Krueger JG. Palmoplantar pustular psoriasis (PPPP) is characterized by activation of the IL-17A pathway. J Dermatol Sci. 2017; 85(1):20–26. doi: 10.1016/j.jdermsci.2016.09.019.
    • Brikos C, O´Neill LA. Signaling of toll-like receptors. Handb Exp Pharmacol. 2018; 183: 21–50. doi: 10.1007/978-3-540-72167-3_2.
    • Clark RA. Resident memory T cells in human health and disease. Sci Transl Med. 2015; 7 (269):269–274. doi: 10.1126/scitranslmed.3010641.
    • Harden JL, Krueger JG, Bowcock AM. The immunogenetics of Psoriasis: A comprehensive review. J Autoimmun. 2015 Nov; 64:66–73. doi: 10.1016/j.jaut.2015.07.008.
    • Henseler T, Schmitt-Rau K. A comparison between BSA, PASI, PLASI and SAPASI as measures of disease severity and improvement by therapy in patients with psoriasis. Int J Dermatol. 2018 Oct;47(10):1019–23. doi: 10.1111/j.1365-4632.2008.03753.x. PMID: 18986347.
    • Ibba L, Gargiulo L, Alfano A, Cascio Ingurgio R, Narcisi A, Costanzo A, et al. Anti-IL-23 and anti-IL-17 drugs for the treatment of non-pustular palmoplantar psoriasis: a real-life retrospective study. J Dermatolog Treat. 2023; 34(1):219–238. doi: 10.1080/09546634.2023.2199108. PMID: 37010456.
    • Mitsui A, Tada Y, Takahashi T, Shibata S, Kamata M. Serum IL 33 levels are increased in patients with psoriasis. Experimental dermatology. 2015; 3(2):234–239.
    • National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI). The practical guide: identification, evaluation, and treatment of overweight and obesity in adults. Bethesda: National Institutes of Health. 2020, NIH publication 00- 4084.
    • Nevoit GV. Systemic dependences of changes in body composition with the progression of non-communicable diseases. World of medicine and biology. 2021;3 (77):132–137. 10.26724/2079-8334-2021-3-77-132-137
    • Suganami T, Tanimoto-Koyama K, Nishida J. Role of the Tolllike receptor 4/NF-kappaB pathway in saturated fatty acidinduced inflammatory changes in the interaction between adipocytes and macrophages. Arterioscler Thromb Vasc Biol. 2017; 27: 84–91. doi: 10.1161/01.ATV.0000251608.09329.9a.
    Publication of the article «World of Medicine and Biology» №2(84), 2023 year, 065-068 pages, index UDK 616.517–056.5-085
    DOI 10.26724/2079-8334-2023-2-84-65-68